Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis

References

• Montes-Moreno S, Montalban C, Piris MA. Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge. Leuk Lymphoma. 2012;53:185–194.
   PubMed Web of Science ®Google Scholar
• Delecluse HJ, Anagnostopoulos I, Dallenback F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with human immunodeficiency virus infection. Blood. 1997;89:1413–1420.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Winer ES, Stachurski D, et al. HIV-negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuk. 2011;11:185–189.
   PubMed Web of Science ®Google Scholar
• Borenstein J, Pezzella F, Gatter KC. Plasmablastic lymphomas may occur as post-transplant lymphoproliferative disorders. Histopathology. 2007;51:774–777.
   PubMed Web of Science ®Google Scholar
• Van Vrancken MJ, Keglovits L, Krause J. Plasmablastic lymphoma following transplantation. Proc (Bayl Univ Med Cent). 2013;26:152–155.
   PubMedGoogle Scholar
• Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125:2323–2330.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (Revised 4th Edition). IARC: Lyon; 2017.
   Google Scholar
• Morscio J, Dierickx D, Nijs J, et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol. 2014;38:875–886.
   PubMed Web of Science ®Google Scholar
• Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008;83:804–809.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Non-Hodgkin’s Lymphomas (Version 1.2017). [Internet]; [cited 2017 Feb 4]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
   Google Scholar
• Saba NS, Dang D, Saba J, et al. Bortezomib in plasmablastic lymphoma: A case report and review of the literature. Onkologie. 2013;36:287–291.
   PubMed Web of Science ®Google Scholar
• Bibas M, Grisetti S, Alba L, et al. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. JCO. 2010;28:e704–e708.
   PubMed Web of Science ®Google Scholar
• Bose P, Thompson C, Gandhi D, et al. AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib. Eur J Haematol. 2009;82:490–492.
   PubMed Web of Science ®Google Scholar
• Cao C, Liu T, Zhu H, et al. Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review. Clin Lymphoma Myeloma Leuk. 2014;14:e145–e150.
   PubMedGoogle Scholar
• Dasanu CA, Bauer F, Codreanu I, et al. Plasmablastic haematolymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib. Hematol Oncol. 2013;31:164–166.
   PubMed Web of Science ®Google Scholar
• Lipstein M, O’Connor O, Montanari F, et al. Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10:E43–E46.
   PubMedGoogle Scholar
• Yan M, Dong Z, Zhao F, et al. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab. Eur J Haematol. 2014;93:77–80.
   PubMed Web of Science ®Google Scholar
• Fedele PL, Gregory GP, Gilbertson M, et al. Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma. Ann Hematol. 2016;95:667–668.
   PubMed Web of Science ®Google Scholar
• Fernandez-Alvarez R, Gonzalez-Rodriguez AP, Rubio-Castro A, et al. Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients. Leukemia Lymphoma. 2016;57:463–466.
   PubMed Web of Science ®Google Scholar
• Cencini E, Fabbri A, Guerrini S, et al. Long-term remission in a case of plasmablastic lymphoma treated with COMP (cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) and bortezomib. Eur J Haematol. 2016;96:650–654.
   PubMed Web of Science ®Google Scholar
• Akce M, Chang E, Haeri M, et al. Bortezomib, ifosfamide, carboplatin, and etoposide in a patient with HIV-negative relapsed plasmablastic lymphoma. Case Reports Hematol. 2016; Article ID 3598547:1–6.
   PubMed Web of Science ®Google Scholar
• Hirosawa M, Morimoto H, Shibuya R, et al. striking response of plasmablastic lymphoma of the oral cavity to bortezomib: a case report. Biomarker Res. 2015;3:1–4.
   Web of Science ®Google Scholar
• Castillo JJ, Reagan JL, Sikov WM, et al. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015;169:352–355.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99:2685–2693.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115:3008–3016.
   PubMed Web of Science ®Google Scholar
• Tchernonog E, Faurie P, Coppo P, et al. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol. 2017;28:843–848.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113:6069–6076.
   PubMed Web of Science ®Google Scholar
• Offner F, Samoilova O, Osmanov E, et al. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 2015;126:1893–1901.
   PubMed Web of Science ®Google Scholar